1 / 12

Stemina Biomarker Discovery Wisconsin Science & Technology Symposium July 17 & 18, 2008

Stemina Biomarker Discovery Wisconsin Science & Technology Symposium July 17 & 18, 2008. Elizabeth L.R. Donley, CEO bdonley@stemina.com 608-204-0104 (w) 608-577-9209 (c). WARF General Counsel and Director of Business Development WiCell Research Institute Managing Director

uriah
Télécharger la présentation

Stemina Biomarker Discovery Wisconsin Science & Technology Symposium July 17 & 18, 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stemina Biomarker Discovery Wisconsin Science & Technology Symposium July 17 & 18, 2008 Elizabeth L.R. Donley, CEO bdonley@stemina.com 608-204-0104 (w) 608-577-9209 (c)

  2. WARF General Counsel and Director of Business Development WiCell Research Institute Managing Director Registered patent attorney Extensive contract and corporate legal experience J.D. – University of Wisconsin Law School M.B.A.-Finance – University of Wisconsin M.S.-Bacteriology – University of Wisconsin Elizabeth L.R. Donley, CEO

  3. Gabriela Cezar of biotech startup Stemina is unraveling the chemistry of autism.

  4. Stemina combines two ground breaking technologies, human embryonic stem cells and metabolomics Stemina’s platform identifies small molecule biomarkers for drug screening and drug development in an all human system These small molecules can be metabolomic biomarkers for diagnostics Study reveals potential diagnostic biomarkers of Autism Scientific Platform

  5. What is possible Phenotype Genomics What makes it happen Proteomics What is happening Metabolomics

  6. Screen using human embryonic stem cells to predict whether a drug will cause birth defects in a developing human embryo Rodent models are only about 50% predictive of birth defects in a human embryo hES cells reveal biomarkers to prevent, diagnose or manage birth defects First Product

  7. Developmental Toxicity Screen

  8. November 2006: Incorporated in Wisconsin May 2007: Business plan developed and 1st round fund raising begun November 2007: Open state-of-the-art facilities at UW Research Park December 2007: First round complete Target Q4 2008: Developmental toxicity screen complete Timeline

  9. Raised $2.5 million in seed funding $1 million in grants and loans from State of Wisconsin Qualified for QNBV tax credits under Act 255 $1.5 million in angel financing Valuation $4 million pre-money, $5.5 million post Side fund open through DaneVest to max of $250k Hired excellent scientific team PhD level analytical chemist from Abbott Labs Cell biologist with experience growing hESC PhD level Bio-informaticist from University of Arkansas Medical Center Business Update

  10. Proprietary metabolomics technology: Exclusive license to Dr. Cezar’s patent applications on hES cells and metabolomics held by WARF Non-exclusive license to Dr. James Thomson’s hES cell patent portfolio held by WARF First in metabolomic biomarkers of hES cells Large market size Strong scientific team State-of-the-art facilities and instrumentation Stemina Advantage

  11. Q4 2008 - Complete Developmental Toxicity Assay Q1 2009 - Raise money to expand staff Q1 2009 - Begin marketing Dev Tox Assay to pharmaceutical and biotech customers 2009 & 2010 - Continue work on Autism diagnostic biomarkers and cardiac toxicity metabolomics drug screen Exit through acquisition Next Steps

  12. Questions? Elizabeth L.R. Donley, CEO bdonley@stemina.com 608-204-0104 (w) 608-577-9209 (c)

More Related